Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

... Inc. (Nasdaq: ISIS ), the leader in antisense therapeutics, today announced that management ... has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug ... and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of ...

Isis Pharmaceuticals to Present at Jefferies' 3rd Annual Healthcare Conference

... Inc. (Nasdaq: ISIS ), the leader in antisense therapeutics, today announced that management ... has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug ... and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of ...

Isis Pharmaceuticals to Present at Needham's 8th Annual Life Sciences Conference

... Inc. (Nasdaq: ISIS ), the leader in antisense therapeutics, today announced that management ... has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug ... diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of ...

Isis Pharmaceuticals to Present at Goldman Sachs' 30th Annual Global Healthcare Conference

... Inc. (Nasdaq: ISIS ), the leader in antisense therapeutics, today announced that management ... has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug ... diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of ...

Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO

... a variety of cancers. OGX-011 and OGX-427 are antisense drugs co-discovered by Isis and OncoGenex ... from a Phase 1 trial evaluating LY2181308, an antisense drug discovered by Isis and licensed to Eli Lilly ... to expand the scope of diseases we can treat with antisense drugs," said Brett Monia, Ph.D., Vice President ...

Scientists find shared genetic link between the dental disease periodontitis and heart attack

... is located in a genetic region that codes for an antisense DNA called ANRIL", said Dr. Schaefer, "and that ... messenger RNA, and will express a protein. antisense RNA is complementary to the mRNA, and is often ... RNA to form a duplex. Through this binding, the antisense strand inhibits the protein expression of the ...

Isis Reports Strong Financial Results and Highlights for First Quarter of 2009

... to maintain our leadership in all applications of antisense technology, announcing a new initiative with ... the opportunity to discover and develop ssRNAi antisense drugs ourselves. Second, our satellite company partners continue to advance antisense drugs that we discovered or drugs derived from ...

Isis Scientist Awarded 2009 Ebert Prize

... Sciences entitled "Oral Delivery of antisense Oligonucleotides in Man." His co-authors are ... "Our work demonstrated, for the first time, that antisense drugs could be administered orally. The ... the therapeutic and commercial potential of antisense drugs." The research, which was published in ...

First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy

... employs synthetic DNA-like molecules called antisense as a DNA band-aid to skip over the parts of the ... scientists employed a "cocktail" of antisense called morpholinos to extend the range of this ... with morpholinos requires large doses of the antisense molecules--and the technology is costly and ...

First treatment for muscular dystrophy in sight: Scientists successfully harness exon-skipping

... employs synthetic DNA-like molecules called antisense as a DNA band-aid to skip over the parts of the ... at a time, scientists employed a "cocktail" of antisense called morpholinos to extend the range of this ... with morpholinos requires large doses of the antisense moleculesand the technology is costly and ...

Isis Reports Strong Financial Results and Highlights for Fiscal Year 2008

... million in sublicensing revenue from Alnylam and antisense Therapeutics Limited (ATL). Operating ... reported encouraging clinical data on a number of antisense drugs in our pipeline, including OGX-011 in ... evidence demonstrating the therapeutic benefit of antisense drugs in a variety of diseases. The efficiency ...

Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology

... discovered by Isis. In both presentations, antisense drugs being developed by Isis' partners OncoGenex ... "The progress our partners are making with our antisense drugs demonstrate the potential of antisense technology to provide new, first-in-class ...

A potential route for human tumor gene therapy

... needed to know whether the intervention of the antisense NHE1 gene can decrease type 1 Na+/H+ exchange of ... cells. The purpose of transfection of the antisense NHE1 gene into the human gastric carcinoma cell line SGC-7901 is to investigate the effects of antisense therapy targeting the NHE1 gene on the malignant ...

Isis Reports Financial Results and Highlights for First Quarter of 2008

... development and commercialization of antisense drugs for CNS and certain rare ... payment with the selection of an antisense drug candidate to advance into development. ... reported encouraging Phase 2 data of OGX-011, an antisense drug in clinical studies in patients with ...

FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen

... this quarter. Mipomersen is a second-generation antisense drug that reduces the production of apoB-100, a ... has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug ... metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety ...

Isis Reports Financial Results and Highlights for Fiscal year 2007

... "We continue to place carefully selected antisense drugs in the hands of dedicated and highly ... also expanding the therapeutic reach of our antisense technology," added Ms. Parshall. "In addition, we ... just the beginning of value creation from Isis' antisense platform and look forward to an exciting upcoming ...

Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS

... to death. ISIS 333611, a second-generation antisense drug, is Isis' first drug treating ... we demonstrated that direct delivery of an antisense drug onto the spinal fluid via an implantable ... ISIS 333611 ISIS 333611 is a second-generation antisense drug in development for the treatment of ALS ...

Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases

... the development and commercialization of certain antisense drugs. Excaliard made an upfront payment to Isis ... area of unmet medical need, and we believe that antisense offers unique advantages in this area for ... development." "The broad applicability of our antisense technology enables us to build a substantial and ...

Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes

... of this complex disease. The productivity of antisense technology has allowed Isis to rapidly evaluate ... we have seen in the animal models. We know that antisense drugs distribute most readily to the ... several animal species that ISIS 388626 and other antisense inhibitors of SGLT2 effectively reduce target ...

Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007

... including diabetic macular edema. "Because our antisense technology enables us to rapidly discover so many highly selective antisense drugs to diverse and important disease targets, ... has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug ...

New treatment boosts muscle function in myasthenia gravis

... junction, where nerves connect with muscles. antisense is a synthetic, short segment of DNA that locks ... is the first time weve been able to show that antisense is effective and safe when taken orally for a ... American Academy of Neurology. Oral delivery of antisense has long been sought after since it is expected ...

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2009 Financial Results Conference Call

... partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are ... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and ...

Webcast Alert: Isis Pharmaceuticals To Provide General Corporate Update in Conjunction with 2009 Annual Meeting of Stockholders

... partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and ...

Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference

... partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis is a ...

Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis

... partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis is a ...

Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review

... partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis ...

Industry Experts and Global Regulators to Discuss Oligonucleotide-Based Therapeutics Issues

... siRNAs Non-Hybridization Dependent Oligonucleotides antisense Oligonucleotide Discovery and Development Emerging Oligonucleotide ... for Manipulating MicroRNAs Pathways Clinical applications of antisense Oligonucleotides Clinical Applications of Aptamers Clinical ...

Isis to Receive $4.6 Million From Alnylam

... partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis ...

Isis Announces Approximately $2.8 Million in Government Grants and Contracts Awarded to its Ibis Subsidiary to Advance Ibis' Pathogen Identification Technology

... partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are ... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis ...

Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy

... sarcoma. Phase II trials are set to begin for survivin ASO, an antisense molecule targeted at solid tumors that Lilly is developing with its partner, ISIS Pharmaceuticals; a second antisense molecule targeted at solid tumors, eIF-4E ASO, is also set to begin ...

Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months

... About ISIS 301012 and Cholesterol ISIS 301012 is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the ... partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are ...

Isis Acquires Symphony GenIsis

... & Johnson company, to discover, develop and commercialize up to four antisense drugs. The collaboration includes licensing of two of the drugs previously ... partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are ...

JCI table of contents: Sept. 4, 2007

... EDITOR'S PICK: It's a knock out: eIF4E-specific antisense oligonucleotides knock down cancer A new study by Jeremy Graff and ... developed. In this study, the intravenous administration of eIF4E-specific antisense oligonucleotides (ASOs) to mice bearing human tumors substantially ...

New Drug Aids Muscle Function in Myasthenia Gravis

... Neuroscience Ltd. "This is the first time we've been able to show that antisense is effective and safe when taken orally for a neurological disease," study ... planned to study the effects of the drug over a longer period of time. antisense is a synthetic, short segment DNA that blocks production of specific ...

Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference

... will moderate is titled, "RNA Therapeutics - Are We Leveraging on the Promise?" It will cover the current state of development of siRNA, miRNA, antisense and aptamar therapeutics and examine how companies are capitalizing on the promise of the field. Panelists will include Paul Burke, Ph.D., Executive ...

Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development

... Neurodyn, Inc., Charlottetown, Prince Edward Island, Canada Validation of LRRK2 as a drug target for treatment of Parkinson's disease using antisense technology Alejandro Lloret, PhD, Isis Pharmaceuticals, Inc., Carlsbad, California Optimizing lead series of small molecule ...

Small Molecule Might Play Big Part in Lung Cancer

... To test their hypothesis that miR-21 and EGFR may make attractive targets for therapy, the researchers tested two experimental compounds: an antisense molecule designed to bind to the RNA and essentially turn it off; and a compound called AG1478, which targets the cell's EGFR and tyrosine kinase ...

Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis

... oligonucleotide industry. Solid support is the base structure used in the synthesis of oligonucleotides, including diagnostic probes and primers, antisense including RNAi, microRNA, DNA-based and aptamer drugs and represents a substantial portion of the cost to manufacture these oligonucleotides. The ...

Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services

... to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry, fine chemical manufacture, custom peptides and antisense oligo production. Dalton provides cGMP manufacturing and sterile filling services to its customers at any stage of the regulatory process (Phase I, ...

Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement

... to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry, fine chemical manufacture, custom peptides and antisense oligo production. Dalton provides cGMP manufacturing and sterile filling services to its customers at any stage of the regulatory process (Phase I, ...